CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma

被引：4

作者：

Hadidi, Samer Al ^{[1
,3
]}

Cliff, Edward R. S. ^{[2
]}

机构：

[1] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, Myeloma Ctr, Little Rock, AR USA

[2] Harvard Med Sch, Brigham & Womens Hosp, Program Regulat Therapeut & Law, Boston, MA USA

[3] Univ Arkansas Med Sci, Myeloma Ctr, Winthrop P Rock efeller Canc Inst, Little Rock, AR 72205 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2023年 / 182卷

关键词：

D O I：

10.1016/j.ejca.2022.12.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1 / 2

页数：2

共 50 条

[31] DEVELOPMENT OF A NOVEL ANTI-MULTIPLE MYELOMA CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY
Hay, Chuck
Faber, Mary
Adeyanju, Kemi
Medin, Jeffrey
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A896 - A896
[32] BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma
Yang, Jinrong
Zhou, Weilin
Li, Dan
Niu, Ting
Wang, Wei
CANCER LETTERS, 2023, 553
[33] Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma
Dong, Rujiao
Wang, Yudi
Sun, Xiaohong
Lin, Yuanyuan
Luo, Yuqing
Xing, Chongyun
Sun, Lan
Zhang, Shenghui
Yu, Kang
Jiang, Songfu
Chen, Yi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (12): : 911 - 916
[34] Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma
Dingli, Sarah
Rothweiler, Paul
Binder, Moritz
Cook, Joselle
Gertz, Morie A.
Hayman, Suzanne
Kapoor, Prashant
Kourelis, Taxiarchis
Kumar, Shaji K.
Siddiqui, Mustaqeem
Warsame, Rahma
Lin, Yi
Erdman, Arthur G.
Dingli, David
LEUKEMIA, 2025, : 1005 - 1008
[35] Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma
Zhou, Dian
Wang, Ying
Cheng, Hai
Zhu, Lili
Chen, Wei
Li, Hujun
Zhang, Xiaotian
Xia, Jieyun
Qi, Yuekun
Ma, Sha
Zhu, Feng
Yan, Zhiling
Qi, Kunming
Sang, Wei
Sun, Haiying
Li, Depeng
Cao, Jiang
Li, Zhenyu
Xu, Kailin
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2023, 29 (02) : 179 - 185
[36] Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
Costa, Bruno Almeida
Flynn, Jessica
Nishimura, Noriko
Devlin, Sean M.
Farzana, Tasmin
Rajeeve, Sridevi
Chung, David J.
Landau, Heather J.
Lahoud, Oscar B.
Scordo, Michael
Shah, Gunjan L.
Hassoun, Hani
Maclachlan, Kylee
Hultcrantz, Malin
Korde, Neha
Lesokhin, Alexander M.
Shah, Urvi A.
Tan, Carlyn R.
Giralt, Sergio A.
Usmani, Saad Z.
Nath, Karthik
Mailankody, Sham
BLOOD CANCER JOURNAL, 2024, 14 (01):
[37] Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
Timmers, Marijke
Roex, Gils
Wang, Yuedi
Campillo-Davo, Diana
Van Tendeloo, Viggo F., I
Chu, Yiwei
Berneman, Zwi N.
Luo, Feifei
Van Acker, Heleen H.
Anguille, Sebastien
FRONTIERS IN IMMUNOLOGY, 2019, 10
[38] Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia
Zhang, Xian
Li, Jing-Jing
Lu, Pei-Hua
CHINESE MEDICAL JOURNAL, 2020, 133 (04) : 474 - 482
[39] Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy
Schroeder, Torsten
Martens, Tjark
Chitadze, Guranda
Yalcin, Fatih
Trautmann, Heiko
Brueggemann, Monika
Heinen, Christine
Nakov, Philipp
Albici, Anca Maria
Spath, Nicolas
Sprenger, Lukas
Kramp, Laura Jane
Ritgen, Matthias
Wellnitz, Dominique
Simon, Maciej
Lippross, Sebastian
Iaccarino, Ingram
Klapper, Wolfram
Fransecky, Lars
Valerius, Thomas
Schub, Natalie
Pott, Christiane
Baldus, Claudia D.
Stoelzel, Friedrich
BLOOD, 2023, 142
[40] CARDIAC ADVERSE EVENTS ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY: A SYSTEMATIC REVIEW
Thotamgari, Sahith Reddy
Grewal, Udhayvir
Shaik, Likhita
Babbili, Akhilesh
Dominic, Paari
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1901 - 1901

← 1 2 3 4 5 →